RaQualia Pharma Inc. (TYO:4579)
Japan · Delayed Price · Currency is JPY 501.00
+7.00 (1.42%)
Aug 6, 2026, 11:30 AM JST
RaQualia Pharma Financials Overview
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 3,817 | 3,979 | 3,107 | 1,901 | 2,918 | 2,776 |
Revenue Growth | 11.45% | 28.07% | 63.44% | -34.85% | 5.12% | 150.77% |
Gross Profit Gross Profit Growth | 3,146 | 3,267 | 2,482 | 1,656 | 2,687 | 2,455 |
Operating Income Operating Income Growth | 230.41 | 483 | -213 | -337 | 867 | 708 |
Net Income Net Income Growth | 52.64 | 273 | -495 | -323 | 723 | 755 |
Earnings Per Share EPS Growth | 2.11 | 11.36 | -22.87 | -14.95 | 34.47 | 36.03 |
EPS Growth | - | - | - | - | -4.34% | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Japan Japan Growth | 1,067 | 710.93 | 6.11 | 741.66 | 1,187 |
United States of America United States of America Growth | 861 | 1,129 | 1,091 | 1,142 | 1,004 |
Asia Asia Growth | 2,051 | 1,256 | 800.8 | 1,034 | 584.83 |
Others Others Growth | - | 12.26 | 3.51 | - | - |
Total Total Growth | 3,980 | 3,108 | 1,901 | 2,918 | 2,776 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 4,495 | 3,243 | 3,341 | 3,763 | 3,925 | 2,658 |
Total Debt Total Debt Growth | 2,789 | 2,899 | 3,450 | 366 | 220 | 38 |
Net Cash (Debt) Net Cash Growth | 1,706 | 344 | -109 | 3,397 | 3,705 | 2,620 |
Net Cash Growth | - | - | - | -8.31% | 41.41% | 26.69% |
Net Cash Per Share Net Cash Per Share Growth | 68.30 | 14.30 | -5.04 | 157.22 | 176.57 | 124.93 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 203.17 | -354 | 180 | -718 | 1,480 | 366 |
Capital Expenditures CapEx Growth | -66.16 | -67 | -96 | -205 | -31 | -92 |
Free Cash Flow Free Cash Flow Growth | 137.01 | -421 | 84 | -923 | 1,449 | 274 |
Free Cash Flow Growth | -32.88% | - | - | - | 428.83% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 82.43% | 82.11% | 79.88% | 87.11% | 92.08% | 88.44% |
Operating Margin | 6.04% | 12.14% | -6.86% | -17.73% | 29.71% | 25.50% |
Pretax Margin | 6.55% | 10.98% | -11.52% | -15.47% | 29.13% | 31.66% |
Profit Margin | 1.38% | 6.86% | -15.93% | -16.99% | 24.78% | 27.20% |
FCF Margin | 3.59% | -10.58% | 2.70% | -48.55% | 49.66% | 9.87% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 233.89 | 90.48 | - | - | 35.74 | 32.58 |
Forward PE | - | 16.89 | 15.07 | 19.50 | 74.48 | 78.27 |
P/FCF Ratio | 93.85 | - | 99.83 | - | 17.84 | 89.79 |
PS Ratio | 3.37 | 6.21 | 2.70 | 7.83 | 8.86 | 8.86 |